TABLE 3.
Results of subgroup analysis.
| Analysis Perspective | HR for OS (95% CI) | HR for PFS (95% CI) | China | United States | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 a | Model 2 a | Model 1 b | Model 2 b | Model 1 b | Model 2 b | |||||||||
| ICER, $/QALY (range) | Cost-effectiveness probability of adebrelimab, % | ICER, $/QALY (range) | Cost-effectiveness probability of adebrelimab, % | ICER, $/QALY (range) | Cost-effectiveness probability of adebrelimab, % | ICER, $/QALY (range) | Cost-effectiveness probability of adebrelimab, % | ICER, $/QALY (range) | Cost-effectiveness probability of adebrelimab, % | ICER, $/QALY (range) | Cost-effectiveness probability of adebrelimab, % | |||
| Age | p-value = 1.00 | p-value = 1.00 | p-value = 0.02 | p-value = 0.02 | p-value< 0.001 | p-value = 1.00 | ||||||||
| <65 years | 0.71 (0.54.0.93) | 0.70 (0.54,0.91) | 114488.30 (49332.50,dominated) | 0.10% | 230743.97 (97490.80,dominated) | 0.00% | 96342.82 (41813.80, dominated) | 0.70% | 95562.06 (41484.60, dominated) | 0.70% | 64068.00 (3158.83, 93764.90) | 40.50% | 1220182.88 (189491.00, dominated) | 0.00% |
| ≥65 years | 0.70 (0.48,1.00) | 0.62 (0.43,0.89) | 144397.20 (45898.30,dominated) | 0.00% | 283024.75 (88861.30,dominated) | 0.00% | 122762.00 (39190.90, dominated) | 0.00% | 121837.37 (38897.60, dominated) | 0.00% | 39204.90 (predominant,49093.61) | 79.40% | 1510637.43 (102132.00, dominated) | 0.00% |
| Sex | p-value = 0.37 | p-value = 1.00 | p-value = 0.29 | p-value = 0.34 | p-value< 0.001 | p-value = 1.00 | ||||||||
| Male | 0.72 (0.57–0.92) | 0.72 (0.57,0.90) | 104510.30 (50328.60,dominated) | 0.10% | 211236.26 (99542.10,dominated) | 0.00% | 87851.81 (42645.30, dominated) | 0.60% | 87133.83 (42309.10, dominated) | 0.70% | 75294.09 (predominant,110274.00) | 30.80% | 1081565.78 (205669.00, dominated) | 0.00% |
| Female | 0.62 (0.37,1.05) | 0.55 (0.33,0.90) | 1130910.00 (43517.40,dominated) | 0.40% | 2218498.39 (83528.70,dominated) | 0.00% | 961189.10 (37270.70, dominated) | 0.20% | 953978.79 (36997.40, dominated) | 0.30% | 96924.76 (18250.30, 183247.00) | 93.00% | 13560570.20 (54709.20, dominated) | 0.00% |
| ECOG performance status | p-value = 1.00 | p-value = 1.00 | p-value = 0.01 | p-value = 0.12 | p-value< 0.001 | p-value = 1.00 | ||||||||
| 0 | 0.83 (0.46,1.52) | 0.62 (0.35,1.10) | 79562.05 (32413.30,dominated) | 0.00% | 149365.46 (59963.60,dominated) | 0.00% | 68668.06 (28110.90, dominated) | 0.00% | 68202.47 (27919.60, dominated) | 0.00% | 100028.00 (predominant,190549.40) | 100.00% | 470017.64 (predominant, dominated) | 0.00% |
| 1 | 0.69 (0.55,0.87) | 0.69 (0.56,0.87) | 134114.10 (55676.10,dominated) | 0.10% | 271679.39 (111048.00,dominated) | 0.00% | 112642.70 (47031.70, dominated) | 0.80% | 111719.67 (46654.40, dominated) | 0.40% | 83154.84 (72877.60, 98531.60) | 4.80% | 1542692.72 (302435.00, dominated) | 0.00% |
| Smoking history | p-value = 0.50 | p-value = 1.00 | p-value< 0.001 | p-value = 0.03 | p-value = 0.02 | p-value = 1.00 | ||||||||
| Current or former smoker | 0.75 (0.59,0.95) | 0.76 (0.60,0.96) | 85728.21 (46785.10,dominated) | 0.20% | 173389.38 (92759.60,dominated) | 0.00% | 72044.74 (39606.90, dominated) | 1.80% | 71453.00 (39291.30, dominated) | 0.60% | 31541.30 (predominant,139191.00) | 51.90% | 796984.23 (158540.00, dominated) | 0.00% |
| Never smoked | 0.59 (0.37,0.95) | 0.44 (0.27,0.71) | dominated (56043.60,dominated) | 0.00% | dominated (105263.00,dominated) | 0.00% | dominated (48361.20, dominated) | 0.00% | dominated (48030.40, dominated) | 0.00% | 40110.90 (predominant,83514.90) | 46.40% | dominated (176196, dominated) | 0.00% |
| LDH concentration at enrolment | p-value = 1.00 | p-value = 1.00 | p-value = 1.00 | p-value = 1.00 | p-value< 0.001 | p-value = 1.00 | ||||||||
| ≤ULN | 0.59 (0.42,0.82) | 0.70 (0.52,0.95) | 3368594.00 (58604.30,dominated) | 0.00% | 7239725.89 (120749.00,dominated) | 0.00% | 2764377.00 (48901.50, dominated) | 0.00% | 2738378.84 (48475.20, dominated) | 0.00% | 40343.10 (predominant,104485.30) | 0.00% | 39453957.30 (424167.00, dominated) | 0.00% |
| >ULN | 0.83 (0.62,1.11) | 0.64 (0.48,0.85) | 77168.73 (42680.90,dominated) | 0.00% | 145955.09 (80319.70,dominated) | 0.00% | 66433.19 (36805.00, dominated) | 0.00% | 65973.60 (36549.00, dominated) | 0.00% | 18045.20 (predominant,30180.65) | 97.50% | 461862.26 (10992.90, dominated) | 0.00% |
| Liver metastases | p-value = 1.00 | p-value = 1.00 | p-value< 0.001 | p-value< 0.001 | p-value< 0.001 | p-value< 0.001 | ||||||||
| Yes | 0.92 (0.65,1.31) | 0.74 (0.51,1.07) | 56901.71 (34890.10,451566.00) | 0.10% | 108515.89 (65772.20,855030.00) | 0.00% | 48845.20 (30067.60, 388607.00) | 2.80% | 48497.38 (29853.70, 385942.00) | 2.80% | 45461.16 (555.62, 61992.90) | 100.00% | 220141.70 (predominant,5039119.00) | 5.70% |
| No | 0.61 (0.46,0.81) | 0.64 (0.50,0.83) | 754648.00 (65521.20,dominated) | 0.00% | 1558544.84 (132075.00,dominated) | 0.00% | 629183.10 (55131.50, dominated) | 0.00% | 623811.91 (54679.50, dominated) | 0.10% | 25042.50 (predominant,78162.40) | 0.00% | 10695836.90 (477105.00, dominated) | 0.10% |
| Brain metastases | ||||||||||||||
| No | 0.68 (0.55,0.85) | 0.65 (0.53,0.81) | 159532.10 (60674.90,dominated) | 0.10% | 319445.66 (120109.00,dominated) | 0.00% | 134573.90 (51396.90, dominated) | 0.00% | 133504.56 (50994.00, dominated) | 0.10% | 27360.56 (predominant,104422.00) | 1.40% | 1853794.24 (358557.00, dominated) | 0.00% |
| Disease stage | ||||||||||||||
| IV | 0.72 (0.58,0.90) | 0.68 (0.55,0.83) | 111606.50 (54415.10,dominated) | 0.00% | 222336.93 (106664.00,dominated) | 0.00% | 94323.77 (46258.50, dominated) | 0.20% | 93581.40 (45903.70, dominated) | 0.10% | 9229.36 (predominant,85020.90) | 17.70% | 1124819.92 (245840.00, dominated) | 0.00% |
| PD-L1 tumour proportion score | p-value = 1.00 | p-value = 1.00 | p-value = 1.00 | p-value = 0.75 | p-value< 0.001 | p-value = 1.00 | ||||||||
| <1% | 0.66 (0.52,0.83) | 0.68 (0.54,0.85) | 183382.00 (61363.10,dominated) | 0.10% | 375342.14 (123427.00,dominated) | 0.00% | 153421.10 (51674.20, dominated) | 0.30% | 152134.11 (51252.00, dominated) | 0.60% | 19070.80 (predominant,45291.21) | 0.00% | 2361549.59 (408089.00, dominated) | 0.00% |
| ≥1% | 0.72 (0.33,1.59) | 0.70 (0.34,1.45) | 107880.80 (29987.60,dominated) | 0.10% | 216508.91 (56315.10,dominated) | 0.00% | 90925.80 (25874.40, dominated) | 0.20% | 90196.27 (25686.30, dominated) | 0.40% | 64967.80 (predominant,93277.80) | 100.00% | 1102113.68 (predominant, dominated) | 0.00% |
a
adebrelimab price was $1382.82.
b
adebrelimab price was the estimated Xmax at the WTP threshold of $37,422 for China and $100,000 for the US.